Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 17, 2012
PRESTIGE BRANDS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-32433 | 20-1297589 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
90 North Broadway, Irvington, New York 10533
(Address of principal executive offices, including Zip Code)
(914) 524-6810
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On May 17, 2012, Prestige Brands Holdings, Inc. (the “Company”) announced financial results for the fiscal quarter and year ended March 31, 2012. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2012 is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The information set forth in Item 2.02 above is incorporated by reference as if fully set forth herein.
On May 17, 2012, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and year ended March 31, 2012 using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”). The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during 2013.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
See Exhibit Index immediately following the signature page.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 17, 2012 | PRESTIGE BRANDS HOLDINGS, INC. | ||
By: | /s/ Ronald M. Lombardi | ||
Name: Ronald M. Lombardi | |||
Title: Chief Financial Officer | |||
EXHIBIT INDEX
Exhibit | Description | |
99.1 | Press Release dated May 17, 2012 announcing the Company's financial results for the fiscal quarter and year ended March 31, 2012 (furnished only). | |
99.2 | Investor Relations Slideshow in use beginning May 17, 2012 (furnished only). | |
Exhibit 99.1
News Release
Prestige Brands Holdings, Inc. Reports Record Fourth Quarter Revenues Up 39.1%; Record Core Organic OTC Revenues Up 14.0%; EPS Exceeds Recent Guidance
May 17, 2012-Irvington, NY-Prestige Brands Holdings, Inc. (NYSE-PBH) today announced record results for the fourth quarter and fiscal year ended March 31, 2012, driven by strong Over-the-Counter Healthcare (“OTC”) organic growth and the completion of the acquisition of 17 brands from GlaxoSmithKline (the “GSK Brands”), the largest acquisition in the Company's history.
Revenues for the fourth fiscal quarter were $134.0 million, $37.6 million or 39.1% above the prior year comparable quarter's results of $96.4 million. Organic revenues for the fourth fiscal quarter grew $7.2 million, or 7.5% over the prior year comparable quarter. Revenues from the Company's nine legacy core OTC brands increased $8.2 million or 14.0% over the prior year comparable quarter. These brands are Chloraseptic®, Clear Eyes®, Compound W®, Little Remedies®, The Doctor's® NightGuard®, Efferdent®, PediaCare®, Dramamine® and Luden's®. Revenues from two months of ownership of the GSK Brands accounted for $30.4 million of the increase. The GSK Brands' acquisition increases the core brand group by five. These brands are Beano®, BC® and Goody's®, and Debrox® in the U.S., and Gaviscon® in Canada.
Gross profit for the fourth fiscal quarter was $68.5 million, $22.2 million, or 47.9% above the prior year comparable quarter of $46.3 million. Excluding charges associated with inventory valuation step-up adjustments of $1.8 million related to the GSK Brands' acquisition, gross profit would have been $70.3 million in the current quarter. Gross margin was 51.1% in the current quarter, which was impacted by 1.4 percentage points from the inventory step-up charges noted above. Excluding these charges, gross margin would have improved to 52.5%. In the prior year comparable quarter, gross margin was 48.1%, which was impacted by 3.8 percentage points from the inventory step-up adjustments of $3.7 million associated with the Blacksmith Brands and Dramamine acquisitions. Excluding these charges, gross margin would have been 51.9%. The year-over-year improvement in gross margin is primarily a result of a higher proportion of revenue generated from the OTC segment.
The Company continued its investment in Advertising and Promotion (“A&P”) during the quarter in
support of its core OTC brands and certain recently acquired OTC brands. A&P for the quarter was $18.5 million, $4.4 million, or 31.3% above the prior year comparable quarter spend of $14.1 million. A&P as a percent of revenue was 13.8% during the fourth fiscal quarter, a modest decline from 14.7% in the prior year comparable quarter. The prior year comparable period included a higher advertising spend against brands newly acquired in the Blacksmith Brands and Dramamine® acquisitions, which was affected by seasonality. Excluding this factor, the normalized A&P spending level continued to increase.
Operating income for the fourth fiscal quarter was $22.6 million, $4.0 million or 21.1% higher than the prior year comparable quarter of $18.6 million. Operating income for fiscal 2012 was impacted by $15.2 million of costs primarily associated with the GSK Brands' acquisition (including transaction costs of $8.1 million, an inventory step-up adjustment of $1.8 million and GSK transition costs of $3.6 million) and $1.7 million of costs associated with the evaluation of the Genomma Lab unsolicited proposal. Excluding these charges, operating income would have been $37.8 million. Operating income for the prior year comparable quarter included $4.5 million of costs associated with the acquisitions of Blacksmith and Dramamine®, including an inventory step-up adjustment of $3.7 million and transaction costs of $0.8 million. Excluding these charges, the prior year operating income would have been $23.1 million. On a comparable basis, excluding the charges noted above in the current and prior year quarter, operating income in the current quarter increased 63.3%.
In the fourth fiscal quarter, the Company's diluted earnings per share from continuing operations was $0.00, which included the GSK acquisition and the impact of the above noted costs. This compares to $0.13 in the prior year comparable quarter, which also included the impact of the above noted costs. Excluding the impact of the charges noted above in each quarter, diluted earnings per share from continuing operations in the fourth fiscal quarter would have been $0.26 compared to $0.18 in the prior year comparable quarter, an increase of 44.4%.
Commentary
“We are pleased with the excellent revenue and adjusted EPS growth in the Company's fourth fiscal quarter. We recorded our seventh consecutive quarter of organic core OTC growth achieving the highest growth rate in almost two years. With this organic growth performance, Prestige ranks near the top of many CPG industry participants” commented Matthew M. Mannelly, President and CEO. “In less than three years, our clear and consistent value creation strategy has taken hold. We have transformed Prestige into the largest independent OTC products company in the U.S. with a proven ability to generate consistent organic growth in our core OTC business coupled with a leading free cash flow profile,” he said.
“This quarter's revenue increase reflects the success of our core OTC brand-building strategy, and includes two months of revenues from this quarter's GSK Brands' acquisition. Consumption was driven by increased A&P support resulting in our brands' growth significantly exceeding category growth. Our nine legacy core OTC brands increased almost 15% despite the soft cough/cold season.”
“For the fiscal year, we achieved record revenues and earnings growth, which exceeded our expectations. Our consistently strong free cash flow continued in fiscal 2012, and helped fund the most transformative event in our history-the acquisition of 17 brands from GSK,” Mr. Mannelly said. “This is a meaningful step toward continued shareholder value creation. Our M&A strategy in action has transformed Prestige into a company with approximately 90% of profits derived from higher growth, higher margin OTC brands,” he said.
“The integration of the GSK Brands, our third acquisition in the past year and a half, is proceeding on schedule. We are excited by the potential created by this opportunity, which significantly enhances our portfolio by adding five new core OTC brands. This acquisition closely aligns with our operating model and we believe it is highly cash generative,” he said.
“We've made a steadfast commitment to creating value by driving core OTC growth, acquiring with an exclusive OTC focus, and strategically managing our portfolio. We have much to do in fiscal 2013. Our new product pipeline is robust. We will continue to develop the potential of our two prior acquisitions, Blacksmith Brands and Dramamine®. Furthermore, we will endeavor to participate in M&A within the OTC space to continue the strategic transformation process. Our confidence in our future is reflected in the guidance we previously provided for fiscal year 2013, anticipating diluted adjusted earnings per share to be in the range of $1.22 to $1.32, which represents an increase of approximately 23% to 33% from our current adjusted EPS,” Mr. Mannelly said. “Based on our strong fourth quarter performance, I am bullish regarding our ability to deliver strong results in fiscal 2013.”
Results by Segment for the Fourth Fiscal Quarter
Revenues for the OTC segment in the fourth fiscal quarter were $109.7 million, an increase of 53.3% over the prior year comparable period revenues of $71.6 million. This was due to revenue increases in six of the Company's nine core OTC brands, as well as the addition of two months of revenues from the newly acquired GSK Brands.
Revenues for the Household Cleaning segment for the fourth fiscal quarter were $24.3 million, a 2.2% reduction over the prior year comparable quarter revenues of $24.8 million. The rate of reduction in this segment has improved over the prior year comparable quarter, primarily as a result of increased distribution of Spic and Span®, as well as the fourth quarter introduction of the Comet® line of stainless steel cleaners.
Fiscal Year 2012
Revenues for fiscal 2012 were $441.1 million, an increase of 31.1%, or $104.6 million, over the prior year's revenues of $336.5 million. Organic revenues for the Company grew $10.7 million or 3.2% during fiscal 2012 over the prior year comparable period. Revenues from the GSK acquisition accounted for $30.4 million of the increase. Blacksmith Brands and Dramamine® contributed $63.5 million of the increase for the period prior to the anniversary of their respective purchases.
Income from continuing operations for fiscal 2012 of $37.2 million was 27.5% higher than fiscal 2011 income from continuing operations of $29.2 million. Income from continuing operations for fiscal 2012 was impacted by $12.9 million of costs primarily associated with the GSK acquisition (including transaction costs of $8.4 million, an inventory step-up adjustment of $1.1 million and GSK transition costs of $2.2 million), costs associated with the evaluation of the Genomma Lab unsolicited proposal of $1.1 million, and $0.1 million of costs as a result of the net amount of the combined loss on extinguishment of debt and settlement gain, net of related tax effects.
Income from continuing operations for fiscal 2011 was impacted by costs of $10.5 million associated with the Blacksmith and Dramamine acquisitions and $0.2 million of a loss associated with the extinguishment of debt, net of related tax effects. Excluding these impacts, income from continuing operations would have been $50.1 million for the current fiscal year compared to $39.9 million for the prior fiscal year, an increase of 25.8%.
Diluted earnings per share from continuing operations for fiscal 2012 was $0.73, which includes the impact of the above noted costs, compared to $0.58 in the prior fiscal year, which included the costs associated with the Blacksmith and Dramamine acquisitions and the extinguishment of debt. Excluding the impact of these charges in the fiscal year, diluted earnings per share from continuing operations in fiscal 2012 would have been $0.99 compared to $0.79 in the prior fiscal year.
Outlook
For fiscal year 2013, which began on April 1, 2012, the Company had previously announced that it expects to report diluted adjusted earnings per share in the range of $1.22 to $1.32. This estimate excludes costs related to the GSK acquisition, and related Transition Services Agreement and integration costs, and costs related to the unsolicited Genomma Lab offer.
Free Cash Flow and Debt
Free cash flow (“FCF”) is a “non-GAAP financial measure” and is presented here because management believes it is a commonly used measure of liquidity, indicative of cash available for debt repayment and acquisitions. The Company defines “free cash flow” as net cash provided by operating activities minus capital expenditures.
The Company's FCF for the fourth quarter ended March 31, 2012 was $19.2 million, a decrease of 22.4% over the prior year comparable period's FCF of $24.8 million. FCF for the fourth quarter was impacted by $8.4 million of working capital investments associated with the GSK acquisition, and $10.5 million of other costs, net of related tax effects. Excluding the impact of these charges, FCF for the fourth quarter ended March 31, 2012 would have been $38.1 million.
For fiscal 2012, FCF totaled $66.8 million, a decrease of 22.3% over the prior year comparable period's FCF of $86.0 million. FCF for fiscal 2012 was impacted by $8.4 million of working capital investments associated with the GSK acquisition and $6.7 million of adjustments, net of related tax effects. Excluding the impact of these charges, FCF for fiscal 2012 would have been $81.9 million.
Conference Call and Accompanying Slide Presentation
The Company will host a conference call to review its fourth quarter and year end results on May 17, 2012 at 8:30 am EST. The toll-free dial-in numbers are 800-884-5695 within North America and 617-786-2960 outside of North America. The conference pass code is "prestige". The Company will provide a live internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Company's Investor Relations page of http://prestigebrands.com. The slide presentation can be accessed just before the call from the Investor Relations page of the website by clicking on Webcasts and Presentations. Telephonic replays will be available for two weeks following the completion of the call and can be accessed at 888-286-8010 within North America and at 617-801-6888 from outside North America. The pass code is 20647616.
About Prestige Brands Holdings, Inc.
The Company markets and distributes brand name over-the-counter and household cleaning products throughout the U.S., Canada, and certain international markets. Core brands now include Chloraseptic® sore throat treatments, Clear Eyes® eye care products, Compound W® wart treatments, The Doctor's® NightGuard® dental protector, the Little Remedies® and PediaCare® lines of pediatric over-the-counter products, Efferdent® denture care products, Luden's® throat drops, Dramamine® motion sickness treatment, BC® and Goody's® analgesics, Gaviscon® antacid, Beano® gas treatment, and Debrox® earwax remover.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "assumptions," "target," "guidance," "outlook," "plans," "projection," "may," "will," "would," "expect," "intend," "estimate," "anticipate," "believe, "potential," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. Forward-looking statements in this news release include, without limitation, statements regarding the impact of our M&A strategy, our ability to integrate and develop the brands that we acquire, our new product pipeline, and our outlook for adjusted earnings per share and our plans for growth. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, although they are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors. A discussion of factors that could cause results to vary is included in the Company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission.
Contact: Dean Siegal
914-524-6819
Prestige Brands Holdings, Inc.
Consolidated Statements of Operations
(Unaudited)
Three Months Ended March 31, | Year Ended March 31, | |||||||||||||||
(In thousands, except per share data) | 2012 | 2011 | 2012 | 2011 | ||||||||||||
Revenues | ||||||||||||||||
Net sales | $ | 133,160 | $ | 95,629 | $ | 437,838 | $ | 333,715 | ||||||||
Other revenues | 836 | 734 | 3,247 | 2,795 | ||||||||||||
Total revenues | 133,996 | 96,363 | 441,085 | 336,510 | ||||||||||||
Cost of Sales | ||||||||||||||||
Cost of sales (exclusive of depreciation shown below) | 65,508 | 50,058 | 213,701 | 165,632 | ||||||||||||
Gross profit | 68,488 | 46,305 | 227,384 | 170,878 | ||||||||||||
Operating Expenses | ||||||||||||||||
Advertising and promotion | 18,547 | 14,122 | 57,127 | 42,897 | ||||||||||||
General and administrative | 24,334 | 11,019 | 56,700 | 41,960 | ||||||||||||
Depreciation and amortization | 3,051 | 2,540 | 10,734 | 9,876 | ||||||||||||
Total operating expenses | 45,932 | 27,681 | 124,561 | 94,733 | ||||||||||||
Operating income | 22,556 | 18,624 | 102,823 | 76,145 | ||||||||||||
Other (income) expense | ||||||||||||||||
Interest income | (14 | ) | (1 | ) | (18 | ) | (1 | ) | ||||||||
Interest expense | 16,361 | 8,810 | 41,338 | 27,318 | ||||||||||||
Gain on settlement | — | — | (5,063 | ) | — | |||||||||||
Loss on extinguishment of debt | 5,409 | — | 5,409 | 300 | ||||||||||||
Total other expense | 21,756 | 8,809 | 41,666 | 27,617 | ||||||||||||
Income from continuing operations before income taxes | 800 | 9,815 | 61,157 | 48,528 | ||||||||||||
Provision for income taxes | 815 | 3,401 | 23,945 | 19,349 | ||||||||||||
Income (loss) from continuing operations | (15 | ) | 6,414 | 37,212 | 29,179 | |||||||||||
Discontinued Operations | ||||||||||||||||
Income from discontinued operations, net of income tax | — | — | — | 591 | ||||||||||||
Loss on sale of discontinued operations, net of income tax | — | — | — | (550 | ) | |||||||||||
Net income (loss) | $ | (15 | ) | $ | 6,414 | $ | 37,212 | $ | 29,220 | |||||||
Basic earnings per share: | ||||||||||||||||
Income from continuing operations | $ | — | $ | 0.13 | $ | 0.74 | $ | 0.58 | ||||||||
Income from discontinued operations and loss on sale of discontinued operations | — | — | — | — | ||||||||||||
Net income | $ | — | $ | 0.13 | $ | 0.74 | $ | 0.58 | ||||||||
Diluted earnings per share: | ||||||||||||||||
Income from continuing operations | $ | — | $ | 0.13 | $ | 0.73 | $ | 0.58 | ||||||||
Income from discontinued operations and loss on sale of discontinued operations | — | — | — | — | ||||||||||||
Net income | $ | — | $ | 0.13 | $ | 0.73 | $ | 0.58 | ||||||||
Weighted average shares outstanding: | ||||||||||||||||
Basic | 50,314 | 50,129 | 50,270 | 50,081 | ||||||||||||
Diluted | 50,992 | 50,555 | 50,748 | 50,338 | ||||||||||||
Prestige Brands Holdings, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands) Assets | March 31, 2012 | March 31, 2011 | |||||
Current assets | |||||||
Cash and cash equivalents | $ | 19,015 | $ | 13,334 | |||
Accounts receivable, net | 60,228 | 44,393 | |||||
Inventories | 51,113 | 39,751 | |||||
Deferred income tax assets | 5,283 | 5,292 | |||||
Prepaid expenses and other current assets | 11,396 | 4,812 | |||||
Total current assets | 147,035 | 107,582 | |||||
Property and equipment, net | 1,304 | 1,444 | |||||
Goodwill | 173,702 | 154,896 | |||||
Intangible assets, net | 1,400,522 | 786,361 | |||||
Other long-term assets | 35,713 | 6,635 | |||||
Total Assets | $ | 1,758,276 | $ | 1,056,918 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities | |||||||
Accounts payable | $ | 26,726 | $ | 21,615 | |||
Accrued interest payable | 13,889 | 10,313 | |||||
Other accrued liabilities | 23,308 | 22,280 | |||||
Total current liabilities | 63,923 | 54,208 | |||||
Long-term debt | |||||||
Principal amount | 1,135,000 | 492,000 | |||||
Less unamortized discount | (11,092 | ) | (5,055 | ) | |||
Long-term debt, net of unamortized discount | 1,123,908 | 486,945 | |||||
Deferred income tax liabilities | 167,717 | 153,933 | |||||
Total Liabilities | 1,355,548 | 695,086 | |||||
Stockholders' Equity | |||||||
Preferred stock - $0.01 par value | |||||||
Authorized - 5,000 shares | |||||||
Issued and outstanding - None | — | — | |||||
Preferred share rights | 283 | — | |||||
Common stock - $0.01 par value | |||||||
Authorized - 250,000 shares | |||||||
Issued - 50,466 shares and 50,276 shares at March 31, 2012 and 2011, respectively | 505 | 503 | |||||
Additional paid-in capital | 391,898 | 387,932 | |||||
Treasury stock, at cost - 181 shares at March 31, 2012 and 160 shares at March 31, 2011 | (687 | ) | (416 | ) | |||
Accumulated other comprehensive loss, net of tax | (13 | ) | — | ||||
Retained earnings (accumulated deficit) | 10,742 | (26,187 | ) | ||||
Total Stockholders' Equity | 402,728 | 361,832 | |||||
Total Liabilities and Stockholders' Equity | $ | 1,758,276 | $ | 1,056,918 | |||
Prestige Brands Holdings, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Year Ended March 31, | |||||||
(In thousands) | 2012 | 2011 | |||||
Operating Activities | |||||||
Net income | $ | 37,212 | $ | 29,220 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation and amortization | 10,734 | 10,108 | |||||
Loss on sale of discontinued operations | — | 890 | |||||
Deferred income taxes | 13,793 | 9,324 | |||||
Amortization of deferred financing costs | 1,630 | 1,043 | |||||
Stock-based compensation costs | 3,078 | 3,575 | |||||
Loss on extinguishment of debt | 5,409 | 300 | |||||
Amortization of debt discount | 1,030 | 702 | |||||
Loss on disposal of equipment | — | 153 | |||||
Changes in operating assets and liabilities, net of effects of acquisitions | |||||||
Accounts receivable | (15,854 | ) | 4,918 | ||||
Inventories | 3,710 | 12,443 | |||||
Prepaid expenses and other current assets | (3,009 | ) | 154 | ||||
Accounts payable | 5,127 | 1,784 | |||||
Accrued liabilities | 4,592 | 12,056 | |||||
Net cash provided by operating activities | 67,452 | 86,670 | |||||
Investing Activities | |||||||
Purchases of equipment | (606 | ) | (655 | ) | |||
Proceeds from sale of property and equipment | — | 12 | |||||
Proceeds from sale of discontinued operations | — | 4,122 | |||||
Acquisition of Blacksmith, net of cash acquired | — | (202,044 | ) | ||||
Proceeds from escrow of Blacksmith acquisition | 1,200 | — | |||||
Acquisition of Dramamine | — | (77,115 | ) | ||||
Acquisition of GSK Brands | (662,800 | ) | — | ||||
Net cash used in investing activities | (662,206 | ) | (275,680 | ) | |||
Financing Activities | |||||||
Proceeds from issuance of Senior Notes | 250,000 | 100,250 | |||||
Proceeds from issuance of 2012 Term Loan and 2010 Term Loan | 650,100 | 112,936 | |||||
Repayment of 2010 Term Loan | (242,000 | ) | — | ||||
Payment of deferred financing costs | (33,284 | ) | (830 | ) | |||
Repayment of long-term debt | (25,000 | ) | (51,087 | ) | |||
Proceeds from exercise of stock options | 889 | 331 | |||||
Shares surrendered as payment of tax withholding | (271 | ) | (353 | ) | |||
Net cash provided by financing activities | 600,434 | 161,247 | |||||
Effects of exchange rate changes on cash and cash equivalents | 1 | — | |||||
Increase (decrease) in cash and cash equivalents | 5,681 | (27,763 | ) | ||||
Cash and cash equivalents - beginning of year | 13,334 | 41,097 | |||||
Cash and cash equivalents - end of year | $ | 19,015 | $ | 13,334 | |||
Interest paid | $ | 34,977 | $ | 17,509 | |||
Income taxes paid | $ | 12,865 | $ | 11,894 | |||
Prestige Brands Holdings, Inc.
Consolidated Statements of Operations
Business Segments
(Unaudited)
Three Months Ended March 31, 2012 | |||||||||||
OTC Healthcare | Household Cleaning | Consolidated | |||||||||
(In thousands) | |||||||||||
Net sales | $ | 109,570 | $ | 23,590 | $ | 133,160 | |||||
Other revenues | 167 | 669 | 836 | ||||||||
Total revenues | 109,737 | 24,259 | 133,996 | ||||||||
Cost of sales | 45,953 | 19,555 | 65,508 | ||||||||
Gross profit | 63,784 | 4,704 | 68,488 | ||||||||
Advertising and promotion | 17,149 | 1,398 | 18,547 | ||||||||
Contribution margin | $ | 46,635 | $ | 3,306 | 49,941 | ||||||
Other operating expenses | 27,385 | ||||||||||
Operating income | 22,556 | ||||||||||
Other expense | 21,756 | ||||||||||
Provision for income taxes | 815 | ||||||||||
Loss from continuing operations | (15 | ) | |||||||||
Income from discontinued operations, net of income tax | — | ||||||||||
Loss on sale of discontinued operations, net of income tax | — | ||||||||||
Net loss | $ | (15 | ) | ||||||||
Three Months Ended March 31, 2011 | |||||||||||
OTC Healthcare | Household Cleaning | Consolidated | |||||||||
(In thousands) | |||||||||||
Net sales | $ | 71,390 | $ | 24,239 | $ | 95,629 | |||||
Other revenues | 175 | 559 | 734 | ||||||||
Total revenues | 71,565 | 24,798 | 96,363 | ||||||||
Cost of sales | 33,233 | 16,825 | 50,058 | ||||||||
Gross profit | 38,332 | 7,973 | 46,305 | ||||||||
Advertising and promotion | 12,834 | 1,288 | 14,122 | ||||||||
Contribution margin | $ | 25,498 | $ | 6,685 | 32,183 | ||||||
Other operating expenses | 13,559 | ||||||||||
Operating income | 18,624 | ||||||||||
Other expense | 8,809 | ||||||||||
Provision for income taxes | 3,401 | ||||||||||
Income from continuing operations | 6,414 | ||||||||||
Income from discontinued operations, net of income tax | — | ||||||||||
Loss on sale of discontinued operations, net of income tax | — | ||||||||||
Net income | $ | 6,414 | |||||||||
Year Ended March 31, 2012 | |||||||||||
OTC Healthcare | Household Cleaning | Consolidated | |||||||||
(In thousands) | |||||||||||
Net sales | $ | 344,282 | $ | 93,556 | $ | 437,838 | |||||
Other revenues | 719 | 2,528 | 3,247 | ||||||||
Total revenues | 345,001 | 96,084 | 441,085 | ||||||||
Cost of sales | 143,151 | 70,550 | 213,701 | ||||||||
Gross profit | 201,850 | 25,534 | 227,384 | ||||||||
Advertising and promotion | 51,895 | 5,232 | 57,127 | ||||||||
Contribution margin | $ | 149,955 | $ | 20,302 | 170,257 | ||||||
Other operating expenses | 67,434 | ||||||||||
Operating income | 102,823 | ||||||||||
Other expense | 41,666 | ||||||||||
Provision for income taxes | 23,945 | ||||||||||
Income from continuing operations | 37,212 | ||||||||||
Income from discontinued operations, net of income tax | — | ||||||||||
Loss on sale of discontinued operations, net of income tax | — | ||||||||||
Net income | $ | 37,212 | |||||||||
Year Ended March 31, 2011 | |||||||||||
OTC Healthcare | Household Cleaning | Consolidated | |||||||||
(In thousands) | |||||||||||
Net sales | $ | 234,042 | $ | 99,673 | $ | 333,715 | |||||
Other revenues | 543 | 2,252 | 2,795 | ||||||||
Total revenues | 234,585 | 101,925 | 336,510 | ||||||||
Cost of sales | 97,710 | 67,922 | 165,632 | ||||||||
Gross profit | 136,875 | 34,003 | 170,878 | ||||||||
Advertising and promotion | 36,752 | 6,145 | 42,897 | ||||||||
Contribution margin | $ | 100,123 | $ | 27,858 | 127,981 | ||||||
Other operating expenses | 51,836 | ||||||||||
Operating income | 76,145 | ||||||||||
Other expense | 27,617 | ||||||||||
Provision for income taxes | 19,349 | ||||||||||
Income from continuing operations | 29,179 | ||||||||||
Income from discontinued operations, net of income tax | 591 | ||||||||||
Loss on sale of discontinued operations, net of income tax | (550 | ) | |||||||||
Net income | $ | 29,220 | |||||||||
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, income or loss from discontinued operations or the sale thereof and Non-GAAP Adjusted EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, income or loss from discontinued operations and the sale thereof, gain on settlement, loss on extinguishment of debt, certain other legal and professional fees and acquisition-related costs. We define Non-GAAP Adjusted Income from Continuing Operations as Income from Continuing Operations before incremental interest expense to finance future acquisitions, gain on settlement, loss on extinguishment of debt, certain other legal and professional fees, acquisition-related costs, the applicable tax impacts associated with these items and the tax impacts of state tax rate adjustments and other non-deductible items. We define Non-GAAP Adjusted Net Income as Net Income before gain on settlement, loss on extinguishment of debt, certain other legal and professional fees, acquisition-related costs, income or loss from discontinued operations and the sale thereof, the applicable tax impacts associated with these items and the tax impacts of state tax rate adjustments and other non-deductible items. We define Non-GAAP Free Cash Flow as net cash provided by operating activities less cash paid for capital expenditures. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Net Income and Non-GAAP Free Cash Flow may not be comparable to similarly titled measures reported by other companies.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Income from Continuing Operations, Non-GAAP Adjusted Net Income and Non-GAAP Free Cash Flow because they provide additional ways to view our operations, when considered with both our GAAP results and the reconciliation to net income and net cash provided by operating activities, respectively, which we believe provide a more complete understanding of our business than could be obtained absent this disclosure. Each of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Income from Continuing Operations, Non-GAAP Adjusted Net Income and Non-GAAP Free Cash Flow is presented solely as a supplemental disclosure because: (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing our ability to pursue acquisitions or service or incur indebtedness; and (iii) we use Non-GAAP EBITDA/Non-GAAP Adjusted EBITDA and Non-GAAP Adjusted Net Income internally to evaluate the performance of our personnel and also as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Income from Continuing Operations, Non-GAAP Adjusted Net Income and Non-GAAP Free Cash Flow has limitations and you should not consider these measures in isolation from or as an alternative to GAAP measures such as operating income, income from continuing operations, net income, and net cash flow provided by operating activities, or cash flow statement data prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The following tables set forth the reconciliation of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted Income from Continuing Operations, Non-GAAP Adjusted Net Income and Non-GAAP Free Cash Flow, all of which are non-GAAP financial measures, to GAAP net income and GAAP Net cash provided by operating activities, respectively, our most directly comparable financial measures presented in accordance with GAAP.
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA:
Three Months Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Net Income (Loss) | $ | (15 | ) | $ | 6,414 | ||||
Income from discontinued operations | — | — | |||||||
Interest expense, net | 16,347 | 8,809 | |||||||
Income tax provision | 815 | 3,401 | |||||||
Depreciation and amortization | 3,051 | 2,540 | |||||||
Non-GAAP EBITDA: | 20,198 | 21,164 | |||||||
Adjustments: | |||||||||
Inventory step-up charges associated with acquisitions | 1,795 | 3,729 | |||||||
Legal and professional fees associated with acquisitions | 8,142 | 802 | |||||||
Transition costs associated with GSK | 3,588 | — | |||||||
Unsolicited proposal costs | 1,737 | — | |||||||
Loss on extinguishment of debt | 5,409 | — | |||||||
Total adjustments | 20,671 | 4,531 | |||||||
Non-GAAP Adjusted EBITDA | $ | 40,869 | $ | 25,695 | |||||
Year Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Net Income | $ | 37,212 | $ | 29,220 | |||||
Income from discontinued operations | — | (591 | ) | ||||||
Loss on sale of discontinued operations | — | 550 | |||||||
Interest expense, net | 41,320 | 27,317 | |||||||
Income tax provision | 23,945 | 19,349 | |||||||
Depreciation and amortization | 10,734 | 9,876 | |||||||
Non-GAAP EBITDA: | 113,211 | 85,721 | |||||||
Adjustments: | |||||||||
Inventory step-up charges associated with acquisitions | 1,795 | 7,273 | |||||||
Legal and professional fees associated with acquisitions | 13,807 | 7,729 | |||||||
Transition costs associated with GSK | 3,588 | — | |||||||
Unsolicited proposal costs | 1,737 | — | |||||||
Gain on settlement | (5,063 | ) | — | ||||||
Loss on extinguishment of debt | 5,409 | 300 | |||||||
Total adjustments | 21,273 | 15,302 | |||||||
Non-GAAP Adjusted EBITDA | $ | 134,484 | $ | 101,023 | |||||
Reconciliation of GAAP Income from Continuing Operations to Non-GAAP Adjusted Income from Continuing Operations:
Three Months Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Income (Loss) from Continuing Operations | $ | (15 | ) | $ | 6,414 | ||||
Adjustments: | |||||||||
Inventory step-up charges associated with acquisitions | 1,795 | 3,729 | |||||||
Acquisition related costs | 8,142 | 802 | |||||||
Transition costs associated with GSK | 3,588 | — | |||||||
Unsolicited proposal costs | 1,737 | — | |||||||
Loss on extinguishment of debt | 5,409 | — | |||||||
Tax impact of adjustments | (7,816 | ) | (2,094 | ) | |||||
Total adjustments | 12,855 | 2,437 | |||||||
Non-GAAP Adjusted Income from Continuing Operations | $ | 12,840 | $ | 8,851 | |||||
Year Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Income from Continuing Operations | $ | 37,212 | $ | 29,179 | |||||
Adjustments: | |||||||||
Incremental interest expense to finance Dramamine | — | 800 | |||||||
Inventory step-up charges associated with acquisitions | 1,795 | 7,273 | |||||||
Acquisition related costs | 13,807 | 7,729 | |||||||
Transition costs associated with GSK | 3,588 | — | |||||||
Unsolicited proposal costs | 1,737 | — | |||||||
Gain on settlement | (5,063 | ) | — | ||||||
Loss on extinguishment of debt | 5,409 | 300 | |||||||
Tax impact of adjustments | (8,091 | ) | (5,213 | ) | |||||
Tax impact of state rate adjustments and other non-deductible items | (237 | ) | — | ||||||
Total adjustments | 12,945 | 10,889 | |||||||
Non-GAAP Adjusted Income from Continuing Operations | $ | 50,157 | $ | 40,068 | |||||
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and related Diluted Earnings Per Share:
Three Months Ended March 31, | |||||||||||||
2012 | 2012 Diluted EPS | 2011 | 2011 Diluted EPS | ||||||||||
(In thousands) | |||||||||||||
GAAP Net Income (Loss) | $ | (15 | ) | $ | — | $ | 6,414 | $ | 0.13 | ||||
Adjustments: | |||||||||||||
Inventory step-up charge associated with acquisitions | 1,795 | 0.04 | 3,729 | 0.07 | |||||||||
Legal and professional fees associated with acquisitions | 8,142 | 0.16 | 802 | 0.02 | |||||||||
Transition costs associated with GSK | 3,588 | 0.07 | — | — | |||||||||
Unsolicited proposal costs | 1,737 | 0.03 | — | — | |||||||||
Loss on extinguishment of debt | 5,409 | 0.11 | — | — | |||||||||
Tax impact of adjustments | (7,816 | ) | (0.15 | ) | (2,094 | ) | (0.04 | ) | |||||
Total adjustments | 12,855 | 0.26 | 2,437 | 0.05 | |||||||||
Non-GAAP Adjusted Net Income and Adjusted EPS | $ | 12,840 | $ | 0.26 | $ | 8,851 | $ | 0.18 | |||||
Year Ended March 31, | |||||||||||||
2012 | 2012 Diluted EPS | 2011 | 2011 Diluted EPS | ||||||||||
(In thousands) | |||||||||||||
GAAP Net Income | $ | 37,212 | $ | 0.73 | $ | 29,220 | $ | 0.58 | |||||
Adjustments: | |||||||||||||
Income from discontinued operations | — | — | (591 | ) | (0.01 | ) | |||||||
Loss on sale of discontinued operations | — | — | 550 | 0.01 | |||||||||
Incremental interest expense to finance Dramamine | — | — | 800 | 0.02 | |||||||||
Inventory step-up charge associated with acquisitions | 1,795 | 0.04 | 7,273 | 0.14 | |||||||||
Legal and professional fees associated with acquisitions | 13,807 | 0.27 | 7,729 | 0.15 | |||||||||
Transition costs associated with GSK | 3,588 | 0.07 | — | — | |||||||||
Unsolicited proposal costs | 1,737 | 0.03 | — | — | |||||||||
Gain on settlement | (5,063 | ) | (0.10 | ) | — | — | |||||||
Loss on extinguishment of debt | 5,409 | 0.11 | — | — | |||||||||
Tax impact of adjustments | (8,091 | ) | (0.16 | ) | (5,213 | ) | (0.10 | ) | |||||
Tax impact of state rate adjustments and other non-deductible items | (237 | ) | — | — | — | ||||||||
Total adjustments | 12,945 | 0.26 | 10,548 | 0.21 | |||||||||
Non-GAAP Adjusted Net Income and Adjusted EPS | $ | 50,157 | $ | 0.99 | $ | 39,768 | $ | 0.79 | |||||
Reconciliation of GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow:
Three Months Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Net cash provided by operating activities | $ | 19,459 | $ | 25,011 | |||||
Additions to property and equipment for cash | (248 | ) | (250 | ) | |||||
Non-GAAP Free Cash Flow | $ | 19,211 | $ | 24,761 | |||||
Year Ended March 31, | |||||||||
2012 | 2011 | ||||||||
(In thousands) | |||||||||
GAAP Net cash provided by operating activities | $ | 67,452 | $ | 86,670 | |||||
Additions to property and equipment for cash | (606 | ) | (655 | ) | |||||
Non-GAAP Free Cash Flow | $ | 66,846 | $ | 86,015 | |||||
1 28-75-124 196-18-48 May 17, 2012 Review of Fourth Quarter & FY’12 Results Matthew M. Mannelly, CEO Ronald M. Lombardi, CFO Exhibit 99.2
2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s growth strategies, investments in advertising and promotion, market position, product introductions and innovations, and future financial performance. Words such as "continue," "will," "believe," “intend,” “expect,” “anticipate,” “plan,” “potential,” “estimate,” “may,” “should,” “could,” “would,” and similar expressions identify forward- looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the failure to successfully integrate the GSK brands, the failure to successfully commercialize new and enhanced products, the Company’s inability to deleverage, the effectiveness of the Company’s advertising and promotions investments, further decline in the household cleaning products market, the severity of the cold/cough season, the effectiveness of the Company’s marketing and distribution infrastructure, and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable securities laws, the Company undertakes no obligation to update any forward-looking statement contained herein, whether as a result of new information, future events, or otherwise. Safe Harbor Disclosure
3 FY’12 Q4: A Stellar Quarter Fiscal Year 2012: The Prestige Value Creation Formula Delivers Q4 & FY 2012 Financial Overview Prestige’s Strategy: Delivering Results; Poised for Success 1 2 3 Agenda 4 Our Latest Quarter: Excellent Performance Across the Board
4 FY’12 Objectives: Exceeded Expectations Drive Core OTC growth through proven, increased, and innovative A&P investment Continue development of long term potential of Blacksmith and Dramamine brands following successful integration Stabilize Household through marketing support, new products, and enhanced distribution Continue pursuit of strategic course in transformation process with focus on OTC M&A activity as part of on-going portfolio optimization Maintain strong financial performance while investing for future value creation Expand and upgrade management talent to match Prestige’s scale and growth expectations
5 Strong financial performance for the quarter − Consolidated net revenue growth of 39.1%; 7.5%, excluding the impact of the GSK acquisition − Adjusted EPS(1) of $0.26, up 44.4% versus prior year, and above adjusted EPS provided in recent guidance of $0.23. GSK acquisition added $0.01 to Q4 adjusted EPS − Cash Flow from Operating Activities of $38.4 million, adjusted for one-time and non-recurring items(1) Brand building strategy delivered consistent organic growth for core OTC brands − Core OTC net revenue growth of 14.0% − Highest Core OTC net revenue growth in last seven consecutive quarters of growth Significant improvement in Household segment performance − Meaningful improvement in quarter, net revenue decline of (2.2%) versus (6.9%) in first nine months of FY’12 as a result of new product launches Completed acquisition of GSK brands − Largest acquisition in PBH history – 15 brands closed on 1/31/12 and 2 brands closed on 3/31/12 − Integration on track – current focus on delivering against most critical milestones Solid financial performance oriented towards sustained value creation (1) These adjustments are non-GAAP and are reconciled to cash flow provided by operations on slide 30 Fourth Quarter Highlights
6 $30.4 FY’12 Q4 FY’11 Q4 +39.1% +53.3% +14.0% (2.2%) Net Revenue in millions FY’12 Q4: A Stellar Quarter Strong Momentum Across All Segments Industry Leading Organic Growth Double Digit OTC Growth Strongest Growth in Past 7 Quarters Improved Performance $134.0 +7.5% +10.9% $109.7 +48.9% $86.7 % Growth: $30.4 $20.3
7 Leading Net Organic Revenue Growth(1) Source: Company filings Note: (1) Organic sales growth excludes impact from acquisitions, divestitures, FX rate fluctuations and other factors (2) Represents core OTC organic net revenue growth (3) Represents total company organic net revenue growth excluding GSK brands Median: 6.5% L a te s t Fisc a l Q u a rt er Org a n ic Net Reve n u e G rowt h Core OTC(2) [to come] Total Company(3)
8 Our Latest Quarter: Excellent Performance Across the Board Fiscal Year 2012: The Prestige Value Creation Formula Delivers Q4 & FY 2012 Financial Overview Prestige’s Strategy: Delivering Results; Poised for Success 1 2 3 Agenda 4
9 Proven Value Creation Track Record North America OTC Assets Prestige Value Creation Framework Drive Core OTC Organic Growth Exclusive OTC M&A Focus Strategic Portfolio Management PBH Stock Price +50% $9.00 $13.50 (1) Stock price prior to receipt of Genomma’s unsolicited bid (1) Analgesics Cough & Cold GI Eye & Ear Care Dermatologicals Oral Care Sleep Aids Platforms
10 Robust Pipeline of New Product Introductions…
11 …Supported by a Portfolio of Targeted A&P Strategies
12 Value-added innovation renews interest in the category by fulfilling an unmet need… …Generating incremental volume by bringing new users to the category… …And offering current users a new form Quickly and conveniently makes dentures look and feel cleaner Cleans in 3 minutes and packaged for home and “on the go” convenience Kills 10x more odor- causing bacteria than tablets Positioned to attract growing number of retainer and mouth guard users Source: The Nielsen Company – Bases Study 2011 Efferdent Power Clean Crystals – Consumer Insights Drive Innovation in Denture Care Social Media TV Consumer print Professional endorsement (ADA) Consumer promotions Compelling Consumer Proposition Proven Innovation Strategy Marketing Support Begins May 2012
13 34% of households with children ages 2-12 have a child with motion sickness(1) Estimated 1/3 of the moms use Dramamine Adult Formula but would prefer a kids’ dose Provides incremental volume by offering an adult’s and a children’s form Quick and easy motion sickness relief for children without altering the adult dosage Specific dosage and formula for children ages 2-12 Convenient easy carry travel pill case Top-selling flavor: Grape New Dramamine For Kids – Motion Sickness Relief Designed Just For Children Ages 2 – 12 Social media Internet/website partners Radio Consumer print Professional print ads Consumer promotions Fulfills an Important Consumer Need (1) 2011 Omnibus study Compelling Consumer Proposition Marketing Support Begins May 2012
14 Consumption Growth (FY’11 & FY’12) 148.2% 31.1% (3.6%) 69.0% 24.6% (5.2%) Category Category Prestige’s pediatric platform, including PediaCare® and Little Remedies®, represents approximately ~10% of revenues, after the impact of the GSK acquisition Significantly increased A&P support over last two seasons (20–30%) to build sustainable brand equity Innovative marketing is effective in building consumer connections Multiple brands have presented new long-term opportunities (trade, professional) Retailer support strengthening as a result of strong A&P initiatives and meeting retailer's needs Source: IRI FDMx for the period ending 3/18/12; Prestige consumption data reflects IRI + POS Effectively Building Long-Term Foundation for Pediatric Platform
15 Total A&P (% of Net Revenue)(1) Core OTC A&P (% of Net Revenue)(1) Note: Includes GSK brands in Q4 FY’12 (1) Adjusted in FY’11 to reflect normalized level of A&P spending for Pediacare Consumption Growth Being Driven by Increased & More Effective A&P and New Product Support Spent an Aggregate of $57.1 Million in FY’12 to Support our Business +0.7% pts. +1.6% pts. +3.4% pts. +0.4% pts. vs. Prior Year
16 Category Prestige Q4 (Latest 12 Weeks) FY’12 (Latest 52 Weeks) +3.6% pts. +6.0% pts. +10.7% pts. +4.4% pts. +7.3% pts. +12.2% pts. vs. Category Source: IRI FDMx for the period ending 3/18/12; Prestige consumption data reflects IRI + POS Consumption Growth Significantly Exceeding Category Growth
17 While Consistently Delivering Operating Results, Management’s M&A Strategy has Transformed Prestige ~$200 ~$300 ~$500 5 9 14 Avg. Top 10 Brand Scale: ~$20 ~$25 ~$35 + + GSK Brands + + ~$100 + ~$200 Core OTC Brands: Total OTC Revenue: Dollar values in millions
18 16.5% Blacksmith and Dramamine Brands Proven Brand Building Q4 Net Revenue Growth(1) Consumption Growth(1) New Product Development Incremental A&P Investments Attention at the Trade Category Blacksmith and Dramamine Brands Acquisition Excellence Seamless Transition with Customers Outsourced Model Accelerates Integration Proven Capability +18.4% pts. +17.8% pts. +7.5% pts. Source: IRI FDMx for the period ending 3/18/12; Prestige consumption data reflects IRI + POS (1) Excludes Nasalcrom vs. Category Proven Ability to Acquire, Integrate and Grow Acquired Brands
19 The GSK Acquisition: A Transformative Event
20 Key GSK Brands Have Strong Consumer Franchises… Brand: Category leader and most recommended ear wax removal product by doctors and pharmacists Consumer: Choice driven by professional recommendation and choice at shelf Opportunities: – Continue strong A&P support – Innovation/new products Brand: Significant share in the gas prevention segment Consumer: Loyal, satisfied consumer base Opportunities: – Focus on prevention – Innovation – Increased distribution – New segments Brand: #1 Doctor recommended OTC product for acid reflux Consumer: Highly loyal users drive ~80% of volume Opportunities: – Pursue new users and (dissatisfied) switchers of antacids and H2 inhibitors – Focus messaging on claims relative to competing products Brand: Unique 80-year heritage and differentiated positioning; #1 share of powdered aspirin segment in the U.S. Consumer: Highly loyal users; Core of user base in South Opportunities: – Capture new users by leveraging core brand equities – Innovation – Geographic expansion
21 …and Are Already Being Supported by Compelling Marketing Strategies Stronger media support and healthier investment into event marketing Rivalry ad campaign driven by heavy radio support in southern market Product endorsement by Richard Petty and Trace Atkins NASCAR sponsor Stronger media support Focus on prevention Invest in relationships with pharmacists to maintain #1 standing Continue strong A&P support and drive innovation of new products
22 March April May June Develop FY’13 brand strategies, sales quotas and fiscal plan Select Canadian distributor Finalize contract for new warehouse Visit third party manufacturers and conduct required quality assessments Finalize supplier and service provider agreements Conduct joint business planning with retail customers for GSK products Prepare infrastructure and systems at warehouse Visit third party manufacturers and conduct required quality assessments Select Pharmacovigilance (PV) system Transfer remaining data and management of IT Complete hiring of new staff Visit third party manufacturers and conduct required quality assessments Transition to new warehouse and distribution, including EDI Complete testing on new and updated systems Complete knowledge transfer with GSK counterparts Close out core TSAs by June 30th 2012 with extensions available contractually as needed GSK Integration Update: Delivering on the Critical Milestones
23 Analgesics 17% Cough & Cold 17% GI 14% Eye & Ear Care 14% Dermatologicals 9% Oral Care 8% Sleep Aids 1% Note: The remaining 20% of sales is comprised of Household (including Comet) and other brands (1) Based on FY2012 pro forma Prestige’s Portfolio Management Priority: Building Scale Platforms in Relevant OTC Categories % of PF Revenue(1)
24 Our Latest Quarter: Excellent Performance Across the Board Fiscal Year 2012: The Prestige Value Creation Formula Delivers Q4 & FY 2012 Financial Overview Prestige’s Strategy: Delivering Results; Poised for Success 1 2 3 Agenda 4
25 Summary Financial Performance Dollar values in millions, except per share data (1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the “About Non-GAAP Financial Measures” section. Adjusted EPS is also reconciled to reported EPS on Slide 31 (2) Adjusted in Q4 FY’12 and FY’12 for one-time and non-recurring items and is reconciled to cash flow from operations on slide 30 (3) Q4 FY’11 and FY’11 cash flow from operations excludes $6.9 million of adjustments related to acquisition of Blacksmith Brands and Dramamine $441.1 $336.5 $134.5 $101.1 $0.99 $0.79 $82.6 $66.3 Q4 FY’12 Q4 FY’11 +39.1% +59.1% +44.4% +53.6% $134.0 $40.9 $0.26 $38.4 $25.9 $96.4 $25.7 $0.18 +31.1% +33.2% +25.3% +24.6% FY’12 FY’11 Q 4 FY’ 12 vs. Q 4 FY’ 11 FY’ 12 vs. FY’ 11 (2)(3) (1) (1) (1) (1) (2)(3)
26 Net Revenue grew by $37.6 million or 39.1% over year ago, driven by core OTC growth and acquisition of GSK brands – 7.5% growth for the Company, excluding acquisition of GSK brands – 14.0% growth in core OTC, excluding acquired core GSK brands – GSK brands acquisition added $30.4 million Household revenue trends improve to more modest decline of 2.2% as a result of a significant investment in promotional activities and new product launches Gross margin expanded by 0.5% pts. due to higher proportion of Net Revenue from OTC, including GSK brands, somewhat offset by lower Household Gross margin A&P growth of 31.2% consistent with stated investment levels to drive Net Revenue growth – Prior year A&P included significant investment associated with Pediacare Modest G&A increase of $0.6 million, although decreased as a percentage of Net Revenue by 260bps as a result of acquisition leverage Adjusted earnings per share growth of 44.4% Q4 Consolidated Financial Summary Dollar values in millions, except per share data Note: These Non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our Earnings Releases in the “About Non-GAAP Financial Measures” section Q4 FY’12 Comments Q4 FY'12 Q4 FY'11 % Chg Net Revenue 134.0$ 96.4$ 39.1% Gross Margin 70.3 50.1 40.3% % Margin 52.5% 52.0% A&P 18.5 14.1 31.2% % Net Revenue 13.8% 14.6% G&A 10.9 10.3 5.8% % Net Revenue 8.1% 10.7% Adjusted EBITDA 40.9$ 25.7$ 59.1% % Margin 30.5% 26.7% D&A 3.1 2.5 22.1% % Net Revenue 2.3% 2.6% Operating Income 37.8 23.2 63.1% % Margin 28.2% 24.1% Adjusted Net Incom 12.8$ 8.8$ 50.0% Adjusted Earnings Per Share 0.26$ 0.18$ 44.4% Earnings Per Sha e - As Reported 0.00$ 0.13$ -
27 FY’12 Consolidated Financial Summary Net Revenue grew by $104.6 million or 31.1% over year ago, driven by core OTC growth, full year impact of Blacksmith and Dramamine acquisitions, and Q4 impact of GSK brands acquisition – 3.2% organic Net Revenue growth for the total Company, including comparable periods for Blacksmith and Dramamine – 9.8% organic Net revenue growth for Core OTC – Acquisitions added $102.5 million Gross margin modest decline by 100bps – OTC gross margins down slightly as a result of industry-mandated APAP reformulation – Household gross margin decline as a result of a significant investment in promotional activities and new product launches A&P growth of 33.1% consistent with Net Revenue growth G&A as a percent of Net Revenue decreased by 170bps, as the Company benefited from overhead leverage as a result of acquisitions Adjusted Earnings Per Share growth of 25.3% Dollar values in millions, except per share data Note: These Non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our Earnings Releases in the “About Non-GAAP Financial Measures” section FY’12 Comments FY'12 FY'11 % Chg Net Revenue 441.1$ 336.5$ 31.1% Gross Margin 229.2 178.2 28.6% Gross Margin % 52.0% 53.0% A&P 57.1 42.9 33.1% % Net Revenue 12.9% 12.7% G&A 37.6 34.3 9.6% % Net Revenue 8.5% 10.2% Adjusted EBITDA 134.5$ 101.0$ 33.2% % Margin 30.5% 30.0% D&A 10.7 9.9 8.4% % Net Revenue 2.4% 2.9% Operating Income 123.8 91.1 35.9% % Margin 28.1% 27.1% Adjusted Net Inc me 50.2$ 39.9$ 25.8% Adjusted Earnings Per Share 0.99$ 0.79$ 25.3% Earnings Per Share - As Reported 0.73$ 0.58$ 25.9%
28 Recent Performance Comments FY’12 Net Revenue Growth vs. Prior Year FY’12 Consumption Category PBH HH Management has undertaken a long-term perspective to stabilizing the household segment Recent investment in promotional and new product activity has moderated the Net Revenue decline Expect recent and upcoming initiatives to further stabilize the business over time as well as improve the gross margin profile Source: IRI FDMx for the period ending 3/18/12; Prestige consumption data reflects IRI + POS Focused Initiatives to Stabilize Household are Gaining Traction
29 Net Income and EPS Reconciliation Dollar values in millions, except per share data Note: These Non-GAAP financial measures are being reconciled to their reported GAAP amounts. For Further information about Non-GAAP financial measures, refer to our Earnings Release in the “About Non-GAAP Financial Measures” section 3 Months Ended 12 Months Ended Q4 FY'12 Q4 FY'12 Net Income EPS Net Income EPS Q4 FY'12 As Reported (0.0)$ 0.00$ 37.2$ 0.73$ Adjustments: Inventory Step-Up 1.8 0.04 1.8 0.04 Acquisition Related Costs 8.1 0.16 13.8 0.27 Transition Costs Associated with GSK 3.6 0.07 3.6 0.07 Unsolicited Proposal Costs 1.7 0.03 1.7 0.03 Gain on Settlement - - (5.1) (0.10) Loss on Extinguishment of Debt 5.4 0.11 5.4 0.11 Tax Impact of Adjustments (7.8) (0.15) (8.3) (0.16) Total Adjustments 12.9 0.25 12.9 0.26 Q4 FY'12 Adjusted 12.8$ 0.26$ 50.2$ 0.99$
30 Q4 adjusted cash flow, excluding the impact of acquisitions, totaled approximately $38.4 million Full year adjusted cash flow, excluding the impact of acquisitions totaled, approximately $82.6 million Debt Profile & Financial Compliance: Total Net Debt at 3/31/12 of $1,116 million comprised of: – Cash on hand of $19.0 million – $635 million of term loan – $500 million of bonds Strong Cash Flow from Operations Cash Flow Comments Dollar values in millions Q4 FY'12 FY'12 Net Income (0.0)$ 37.2$ Depreciation & Amortization 3.1 10.7 Other Non-Cash Operating Items 13.7 25.0 Working Capital 2.7 (5.4) Cash Flow from Operations - As Reported 19.5$ 67.5$ GSK Working Cap tal I vestments 8.4 8.4 One-Time Costs, N t of Taxes 10.5 6.7 Cash Flow from Operations - Adjusted 38.4$ 82.6$
31 High Cash Flow Conversion Drives an Even More Rapid Deleveraging… Fiscal year ending March 31 Leverage ratio reflects Net Debt / covenant defined EBITDA = Excluding Acquisitions = Q3 FY’12 Guidance = Revised Guidance
32 …Providing for Increased Acquisition Capacity While We Continue to Grow Core OTC Brands Comments Illustrative Financial Capacity Prestige is already in a position to continue its OTC acquisition strategy Prestige’s existing financing arrangements and rapid deleveraging ability create expanded acquisition capacity – Today, Prestige has sufficient capacity to complete an acquisition in excess of the scale of Blacksmith – Within one year, Prestige would have sufficient capacity to complete an acquisition of the approximately the scale of the GSK Brands – Within two years, Prestige would have sufficient capacity to complete an acquisition equivalent in scale to the combined Blacksmith, Dramamine and GSK Brands’ acquisitions Widely available sources of capital; leverage not a constraint for continued M&A 17 Brands Fiscal year ending March 31 ~$1.0 BN ~$1.7 BN
33 Our Latest Quarter: Excellent Performance Across the Board Fiscal Year 2012: The Prestige Value Creation Formula Delivers Q4 & FY 2012 Financial Overview A Strategy at Work 1 2 3 Agenda 4 Prestige’s Strategy: Delivering Results; Poised for Success
34 1. #1 and #2 brands deliver nearly two-thirds of OTC revenue 2. Core OTC brands generating superior growth and market share gains 3. Scale platforms in highly relevant OTC categories 4. Management’s strategy has transformed Prestige to predominantly an OTC company 5. Proven ability to source, execute, and integrate acquisitions 6. Valuable tax attributes 7. Leading margins and strong cash flow generation 8. Management team experienced at both growing brands and executing seamless M&A transactions What Sets Prestige Apart: Delivering Value Now and Into the Future 1 2 3 4 5 6 7 8
35 Applicable quarter Prior year comparable quarter Dollar values in millions Note: Excludes GSK acquisition Net Revenue YOY % Growth Seven Straight Quarters of Organic Core OTC Growth Excluding Acquisitions
36 trans·for·ma·tion·al The act or an instance of transforming The state of being transformed A marked change for the better
37 The Transformed Prestige: An Improved Profile for Value Creation Pre-Current Mgmt.(1)(4) Current Profile(2)(3)(4) Change Core OTC Brands 5 14 +9 OTC as % of Revenue ~61% ~85% +24% Top 10 OTC Brands Average Scale ~$20 ~$35 +75% Key OTC Category Platforms 4 6 +2 OTC Addressable Market Size ~$10 BN ~$17 BN +70% Net Revenue $296 ~$615 +2.1x A&P Spending ~12% ~15% +300 bps Gross Margin ~52% ~57% +500 bps EBITDA ~$89 ~$215 +2.4x EBITDA Margins ~30% ~34% +400 bps Free Cash Flow ~$69 ~$110 +1.6x Dollar values in millions; unless otherwise specified (1) Based on LTM ending September 2009 (CapitalIQ) (2) Reflects pro forma Prestige including GSK brands (As of 3/31/12) (3) Excludes TSA, integration, acquisition related and other legal and professional costs (4) Financial Profile includes certain items that are Non GAAP financial measures
38 In Less Than Three Years, Prestige is Now the Largest Independent U.S. OTC Platform 38 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 2011 Rank: + 2.5x in Less Than Three Years + 5 Spots Independent OTC Companies Legacy Dollar values in billions Source: Euromonitor (~$22 BN U.S. OTC Retail Sales; 2011) Note: Trademarks belong to respective owners
39 In Less Than Three Years, Management’s Strategy is Delivering Results Clear and consistent strategy focused on: – Transforming Prestige into an OTC company – Driving sustainable core OTC organic growth – Pursuing accretive OTC acquisitions – Building a highly talented leadership team with deep bench strength at all levels Adjusted Net Revenue Adjusted EPS $315 $294 $293 $337 $441 ~$615 Current Management $0.68 $0.67 $0.67 $0.79 $0.99 $1.22 - $1.32 Current Management Dollar values in millions, except per share data. Fiscal year ending March 31 Reaffirmed Guidance Reaffirmed Guidance CAGR (3.6%) CAGR 28.0% CAGR (0.7%) CAGR 23.8%
40 Clear goals for FY’13 to build on success and momentum − Successfully integrate and transition the acquired brands • Supply and demand • Integration continues beyond end of TSA − Develop long-term potential of acquired GSK brands through tested brand investment strategy − Continue to participate in OTC M&A activity as part of on-going portfolio optimization − Deliver FY’13 Adjusted EPS of $1.22 - $1.32, up ~23% to ~33% versus FY’12 EPS, respectively • Excludes estimated adjustments of $0.10 in Q1 and $0.14 for full year(1) − Maintain strong financial performance while investing appropriately for future value creation Continue the strategic course in the transformation process…”it’s a marathon, not a sprint” Solid Outlook for 2013 and Beyond (1) Adjustments reflect GSK acquisition costs, costs related to the Transition Services Agreement, integration costs, and other legal and professional fees
41 OTC M&A Focus Debt Reduction Portfolio Strategy to Drive Organic Growth A&P Driven Growth for Core OTC Brands Investment in Multi-Year New Product Development Pipeline Select investment in Other Brands Significant Tax Shield Incremental to Free Cash Flow Generation Free Cash Flow Used for Rapid Debt Paydown High Conversion of EBITDA to Free Cash Flow Proven M&A Competency Rapid Integration Expertise Value Creation Formula Strong pipeline of M&A targets Prestige Brands: Delivering Value Now and Into the Future Through a Tested Shareholder Value Creation Framework
42 28-75-124 196-18-48 May 17, 2012